COCP Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases...

Stats
Dzisiejszy wolumen	25 084.00
Średni wolumen	13 743.00
Kapitalizacja rynkowa	16.58M
EPS	$0 ( 2024-04-03 )
Następna data zysków	( $-0.540 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.870
ATR14	$0.0220 (1.33%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-18	Frost Phillip Md Et Al	Buy	19 333	Stock Options (Right to Buy)
2023-07-18	Japour Anthony J	Buy	13 567	Stock Options (Right to Buy)
2023-07-18	Martin James Joseph	Buy	30 000	Stock Options (Right to Buy)
2023-07-18	Kornberg Roger D.	Buy	24 417	Stock Options (Right to Buy)
2023-07-18	Lee Sam	Buy	30 000	Stock Options (Right to Buy)

INSIDER POWER
100.00
Last 92 transactions
Buy: 58 610 813 \| Sell: 4 956 864

Cocrystal Pharma Inc Korelacja

10 Najbardziej pozytywne korelacje
ODT	0.916
RELL	0.904
VRAY	0.901
KSPN	0.901
VRM	0.894
ATHX	0.891
ARTNA	0.889
XPDI	0.886
TCDA	0.885
UXIN	0.885

10 Najbardziej negatywne korelacje
AGNCP	-0.908
AGNCO	-0.903
DSEY	-0.895
NYMTL	-0.892
KROS	-0.892
ISRG	-0.889
NVCN	-0.888
FFNW	-0.885
SRPT	-0.885
ROVR	-0.885

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cocrystal Pharma Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$1.39M (0.00 %)
EPS:	$-1.860

FY	2023
Przychody:	$0
Zysk brutto:	$1.39M (0.00 %)
EPS:	$-1.860

FY	2022
Przychody:	$0
Zysk brutto:	$-241 600 (0.00 %)
EPS:	$-4.77

FY	2021
Przychody:	$5.43M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.39

Financial Reports:

No articles found.

Cocrystal Pharma Inc

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.